Crohn’s disease genotypes of patients in remission vs relapses after infliximab discontinuation

Table 2 Characteristics for Crohn’s disease patients still in remission and those who lost remission after discontinuing infliximab

Characteristic	Remaining in remission following discontinuing infliximab (n = 6)	Lost remission following discontinuing infliximab (n = 8)
Male:female (n)	4:2	4:4
Age of Crohn’s disease onset (yr), mean (range)	30 (14-47)	26 (15-38)
Current age (yr), mean (range)	53 (41-60)	41 (25-57)
Duration of disease prior to first infliximab infusion (yr), mean ± SD	15 ± 8.0	10.1 ± 11.3
Age at first infliximab infusion (yr), mean ± SD	45 ± 7.6	36 ± 11.1
Number of infusions, mean ± SD	5.7 ± 3.5	4.7 ± 1.7
Duration of infliximab treatment (mo), mean (range)	12 (3.6-36.2)	7.2 (1.5-15)
Duration of remission after infliximab stopped (yr), mean ± SD	8.1 ± 2.61	1.0 ± 0.62
Disease distribution, n (%)
Ileum	2 (33)	2 (25)
Ileo-colonic	3 (50)	4 (50)
Colon	1 (17)	2 (25)
Current medications in patients who lost remission, n
Adalimumab		4
Infliximab		2
Azathioprine alone		1
No Biological or immunosuppressive therapy3		1

¹All patients still remain in remission at the time of this study;

²Follow-up time from last dose of infliximab to either date of flare or last day of study (July 6, 2011), P < 0.001;

³This patient developed both basal cell and renal cell carcinoma.